bharat biotech
WHO suspends Covaxin supply to UN agencies
The suspension is in response to the outcomes of its post Emergency Use Authorisation inspection held between March 14-22, WHO said
Bharat Biotech gets DCGI nod for intranasal booster dose trials in India
The trials will be done at 9 different sites, with sources adding that the intranasal vaccine is likely to be launched by March
SEC approval for Bharat Biotech's COVID booster intranasal vaccine phase 3 trials
The SEC has asked the Hyderabad-based vaccine manufacturer to submit its revised protocol for trials
Bharat Biotech's partner seeks Covaxin approval in US for children below 18 years
The World Health Organisation on Wednesday granted approval for Emergency Use Listing Covaxin
WHO grants emergency use licence to Bharat Biotech's Covaxin
CDSCO has approved the extension of shelf life of Covaxin up to 12 months from the date of manufacture
Drugs control committee extends shelf life of Bharat Biotech's Covaxin to 12 months
Currently, Covaxin has a shelf life of 6 months with subject to its storage at 2-8 degrees celsius
Bharat Biotech's Covaxin finds place in Oman's list of approved COVID-19 vaccines
All passengers who have received two doses of Covaxin atleast 14 days before the estimated arrival date can travel to Oman
Bharat Biotech's US partner Ocugen files request with FDA for Covaxin trials
Ocugen has already sought regulatory approval from Health Canada for Covaxin to be used in that country
WHO seeks 'additional clarifications' from Bharat Biotech for Covaxin
The clarifications are sought to conduct a final 'risk-benefit assessment' for Emergency Use Listing of the vaccine
WHO to meet next week to consider emergency use listing of Covaxin
Hyderabad-based Bharat Biotech had submitted Expression of Interest on April 19 for its vaccine